- Home
- YALA vs AVTX Comparison
YALA vs AVTX Comparison
Compare YALA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | AVTX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.1M | 982.5M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | YALA | AVTX |
|---|---|---|
| Price | $5.41 | $16.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 370.9K | ★ 845.8K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $5.01 | $9.54 |
| 52 Week High | $8.10 | $24.27 |
Technical Indicators
Market Signals| Indicator | YALA | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 33.40 |
| Support Level | $5.20 | $15.33 |
| Resistance Level | $5.64 | $16.80 |
| Average True Range (ATR) | 0.09 | 1.00 |
| MACD | -0.01 | -0.44 |
| Stochastic Oscillator | 37.04 | 3.25 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.